Key Drivers
- Margin improvement
- Positive cash flow
- Negative equity
AIAI Summary
STLN is shifting from a liquidity turnaround to an operating-leverage thesis, but investors should wait for multiple quarters of sustained free cash flow and margin expansion as contracted capitated revenue scales toward $300M, since negative equity and high debt leave little room for execution errors.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin improvement
- •Positive cash flow
- •Negative equity
STLN's improving margins and quarterly cash flow are encouraging, but persistent losses, negative equity, weakening liquidity, and heavy debt keep the stock financially fragile.
Price Behavior
Key Price Behavior Insights:
- •Strong upward momentum
- •Overbought conditions
- •Key support test
STLN is bullish over the last month but overbought near $6.96–$7.00, so watch $6.60–$6.65 support for consolidation risk.
Sharp advance from $6.17 on 2026-09-11 to $6.96 on 2026-09-18 increases pullback risk
Sentiment & News
Key News Insights:
- •Conference Participation
- •Executive Fireside Chat
- •No Material Updates
Starling Oncology will present at the Wells Fargo Healthcare Conference on September 8, featuring a fireside chat with its CEO and CFO, with no new operational or clinical updates disclosed.
The event may modestly support investor visibility but is unlikely to materially affect the instrument without additional disclosures
Similar Companies in Healthcare
Other companies in the same sector with AI ratings